RxSight (RXST) Q1 FY26 earnings call

RxSight reported a transformational Q2 FY26 highlighted by a major strategic partnership with Alcon that validates its postoperative light-adjustability platform. Under newly appointed CEO Aziz Motivala, the company is pivoting commercial focus toward driving deeper procedure utilization across its 1,166 LDD installed base. While core product revenue faced near-term competitive pressure from market trialing, management withdrew FY26 guidance to realign sales and commercial operations for long-term growth, supported by a fortified balance sheet.